多发性骨髓瘤抗血管生成的新见解。
New Insights in Anti-Angiogenesis in Multiple Myeloma.
机构信息
Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari 70124, Italy.
Department of Biomedical Sciences, and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari 70124, Italy.
出版信息
Int J Mol Sci. 2018 Jul 12;19(7):2031. doi: 10.3390/ijms19072031.
Abstract
Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and involves direct production of angiogenic cytokines by plasma cells and their induction within the bone marrow microenvironment. This article summarizes the more recent literature data concerning the employment of anti-angiogenic therapeutic agents actually used in preclinical models and clinical settings for the treatment of multiple myeloma.
摘要
血管生成是多发性骨髓瘤（MM）进展的一个恒定特征，涉及浆细胞直接产生血管生成细胞因子及其在骨髓微环境中的诱导。本文总结了最近关于在临床前模型和临床环境中实际用于治疗多发性骨髓瘤的抗血管生成治疗剂的文献数据。
相似文献
1
New Insights in Anti-Angiogenesis in Multiple Myeloma.多发性骨髓瘤抗血管生成的新见解。
Int J Mol Sci. 2018 Jul 12;19(7):2031. doi: 10.3390/ijms19072031.
2
Antiangiogenic therapeutic approaches in multiple myeloma.多发性骨髓瘤的抗血管生成治疗方法。
Curr Cancer Drug Targets. 2012 Sep;12(7):768-75. doi: 10.2174/156800912802429346.
3
Angiogenesis in multiple myeloma.多发性骨髓瘤中的血管生成
Chem Immunol Allergy. 2014;99:180-96. doi: 10.1159/000353312. Epub 2013 Oct 17.
4
Role of tumour angiogenesis in haematological malignancies.肿瘤血管生成在血液系统恶性肿瘤中的作用。
Swiss Med Wkly. 2014 Nov 6;144:w14050. doi: 10.4414/smw.2014.14050. eCollection 2014.
5
Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis.多发性骨髓瘤作为骨髓微环境在血管生成调控中作用的模型。
Int Rev Cell Mol Biol. 2015;314:259-82. doi: 10.1016/bs.ircmb.2014.10.004. Epub 2014 Nov 18.
6
Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.接受沙利度胺治疗的多发性骨髓瘤患者：评估临床参数、细胞因子、血管生成标志物、肥大细胞和骨髓CD57 + 细胞毒性T细胞作为预后预测指标。
Haematologica. 2007 Aug;92(8):1075-82. doi: 10.3324/haematol.11208. Epub 2007 Jul 20.
7
Angiogenesis in multiple myeloma.多发性骨髓瘤中的血管生成
Semin Oncol. 2001 Dec;28(6):560-4. doi: 10.1016/s0093-7754(01)90024-7.
8
The evaluation of angiogenesis and matrix metalloproteinase-2 secretion in bone marrow of multiple myeloma patients before and after the treatment.多发性骨髓瘤患者治疗前后骨髓中血管生成和基质金属蛋白酶-2 分泌的评估。
Adv Med Sci. 2013;58(1):118-25. doi: 10.2478/v10039-012-0048-0.
9
Proteasome inhibitors and modulators of angiogenesis in multiple myeloma.蛋白酶体抑制剂和多发性骨髓瘤血管生成的调节剂。
Curr Med Chem. 2011;18(34):5185-95. doi: 10.2174/092986711798184316.
10
Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma.骨髓微环境在诱导多发性骨髓瘤血管生成反应中的重要性。
Oncogene. 2006 Jul 20;25(31):4257-66. doi: 10.1038/sj.onc.1209456. Epub 2006 Mar 6.
引用本文的文献
1
Associations of ANGPT2 expression and its variants (rs1868554 and rs7825407) with multiple myeloma risk and outcome.血管生成素2（ANGPT2）表达及其变体（rs1868554和rs7825407）与多发性骨髓瘤风险及预后的关联。
Front Oncol. 2025 Mar 6;15:1468373. doi: 10.3389/fonc.2025.1468373. eCollection 2025.
2
Evaluation of the antiangiogenic effect of AMG232 in multiple myeloma coculture systems.AMG232在多发性骨髓瘤共培养系统中的抗血管生成作用评估。
Med Oncol. 2025 Mar 13;42(4):107. doi: 10.1007/s12032-025-02659-8.
3
The HOX Gene Family's Role as Prognostic and Diagnostic Biomarkers in Hematological and Solid Tumors.HOX基因家族在血液系统肿瘤和实体瘤中作为预后和诊断生物标志物的作用。
Cancers (Basel). 2025 Jan 15;17(2):262. doi: 10.3390/cancers17020262.
4
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.FGF/FGFR/c-Myc 轴作为多发性骨髓瘤有前景的治疗靶点。
J Exp Clin Cancer Res. 2024 Nov 1;43(1):294. doi: 10.1186/s13046-024-03217-2.
5
Preclinical Evaluation of a Novel Series of Polyfluorinated Thalidomide Analogs in Drug-Resistant Multiple Myeloma.新型多氟代沙利度胺类似物在耐药性多发性骨髓瘤中的临床前评价。
Biomolecules. 2024 Jun 19;14(6):725. doi: 10.3390/biom14060725.
6
Identification of an angiogenesis-related risk score model for survival prediction and immunosubtype screening in multiple myeloma.鉴定多发性骨髓瘤生存预测和免疫亚型筛选的血管生成相关风险评分模型。
Aging (Albany NY). 2024 Feb 5;16(3):2657-2678. doi: 10.18632/aging.205502.
7
Thrombospondin-1 is an endogenous substrate of cereblon responsible for immunomodulatory drug-induced thromboembolism.血栓反应蛋白-1 是 cereblon 的内源性底物，负责免疫调节药物引起的血栓栓塞。
Blood Adv. 2024 Feb 13;8(3):785-796. doi: 10.1182/bloodadvances.2023010080.
8
Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: Impact on disease progression.骨髓间充质干细胞与多发性骨髓瘤细胞之间的通讯：对疾病进展的影响。
World J Stem Cells. 2023 May 26;15(5):421-437. doi: 10.4252/wjsc.v15.i5.421.
9
A novel VEGFR inhibitor ZLF-095 with potent antitumor activity and low toxicity.一种具有强大抗肿瘤活性和低毒性的新型血管内皮生长因子受体（VEGFR）抑制剂ZLF-095。
Heliyon. 2023 Apr 19;9(5):e15152. doi: 10.1016/j.heliyon.2023.e15152. eCollection 2023 May.
10
Uptake-Dependent and -Independent Effects of Fibroblasts-Derived Extracellular Vesicles on Bone Marrow Endothelial Cells from Patients with Multiple Myeloma: Therapeutic and Clinical Implications.成纤维细胞衍生的细胞外囊泡对多发性骨髓瘤患者骨髓内皮细胞的摄取依赖性和非依赖性作用：治疗及临床意义
Biomedicines. 2023 May 8;11(5):1400. doi: 10.3390/biomedicines11051400.
本文引用的文献
1
Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma.抑制雷帕霉素靶蛋白复合物2可抑制多发性骨髓瘤中的肿瘤血管生成。
Oncotarget. 2018 Apr 17;9(29):20563-20577. doi: 10.18632/oncotarget.25003.
2
Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin protein MP0250: a preclinical study.通过VEGF和HGF阻断DARPin蛋白MP0250靶向多发性骨髓瘤中的血管生成：一项临床前研究。
Oncotarget. 2018 Jan 30;9(17):13366-13381. doi: 10.18632/oncotarget.24351. eCollection 2018 Mar 2.
3
Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.用miR-340补充来自老年骨髓基质细胞的外泌体可抑制骨髓瘤相关的血管生成。
Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23.
4
An overview of the role of carfilzomib in the treatment of multiple myeloma.卡非佐米在多发性骨髓瘤治疗中的作用概述。
Expert Opin Pharmacother. 2017 Dec;18(17):1883-1897. doi: 10.1080/14656566.2017.1404575. Epub 2017 Nov 20.
5
Immune Therapies in Multiple Myeloma.多发性骨髓瘤的免疫治疗。
Clin Cancer Res. 2016 Nov 15;22(22):5453-5460. doi: 10.1158/1078-0432.CCR-16-0868.
6
Integration of Novel Agents into the Care of Patients with Multiple Myeloma.新型药物在多发性骨髓瘤患者治疗中的整合应用
Clin Cancer Res. 2016 Nov 15;22(22):5443-5452. doi: 10.1158/1078-0432.CCR-16-0861. Epub 2016 Nov 14.
7
Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.促红细胞生成素在意义未明的单克隆丙种球蛋白病（MGUS）和多发性骨髓瘤患者骨髓内皮细胞血管生成活性中的作用。
Oncotarget. 2016 Mar 22;7(12):14510-21. doi: 10.18632/oncotarget.7587.
8
Targeting vasculogenesis to prevent progression in multiple myeloma.针对血管生成预防多发性骨髓瘤进展。
Leukemia. 2016 May;30(5):1103-15. doi: 10.1038/leu.2016.3. Epub 2016 Feb 3.
9
Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38.用于治疗骨髓瘤的单克隆抗体：靶向信号淋巴细胞激活分子家族成员7（SLAMF7）和CD38
Cancer J. 2016 Jan-Feb;22(1):3-6. doi: 10.1097/PPO.0000000000000172.
10
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.CXCR4通过上皮-间质转化样转录激活调控髓外骨髓瘤。
Cell Rep. 2015 Jul 28;12(4):622-35. doi: 10.1016/j.celrep.2015.06.059. Epub 2015 Jul 16.
Zotero 插件